Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
21. |
ECCT/23/03/03 | Moderna 1273 A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age |
Principal Investigator(s) 1. Prof. Walter Godfrey Jaoko Jaoko Site(s) in Kenya 1. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county) 2. Victoria Biomedical Research Institute (Kisumu county) 3. KEMRI/USAMRD (Kericho county) 4. Kenya Medical Research Institute/USAMRU (Kisumu county) 5. KEMRI CMR-Kar Geno Research Centre (Kisumu county) 6. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county) 7. KEMRI/ CDC (Kisumu county) 8. KEMRI (Kisumu county) 9. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county) |
View |
22. |
ECCT/23/03/02 | Sunrise-3 A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19 |
Principal Investigator(s) 1. Dr. Paul Yonga 2. Dr John Kinuthia 3. DR LUCAS OTIENO TINA Site(s) in Kenya 1. Fountain Projects and Research Office, Clinical Research Centre (FOPRO-CRC) (Kisumu county) 2. KENYATTA NATIONAL HOSPITAL (Nairobi City county) 3. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) |
View |
23. |
ECCT/23/02/07 | Moderna 1273 A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age |
Principal Investigator(s) 1. Dr. Maricianah Onono Onono Site(s) in Kenya 1. KEMRI CMR-Kar Geno Research Centre (Kisumu county) 2. Victoria Biomedical Research Institute (Kisumu county) 3. KEMRI/USAMRD (Kericho county) 4. Kenya Medical Research Institute/USAMRU (Kisumu county) 5. KEMRI CRDR - Clinical Research Nairobi (Siaya county) 6. KEMRI/ CDC (Kisumu county) 7. KEMRI (Kisumu county) 8. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county) 9. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county) |
View |
24. |
ECCT/23/02/04 | mRNA-1273-P203 A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age |
Principal Investigator(s) 1. Dr Victor Mudhune Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. KEMRI/USAMRD (Kericho county) 3. Kenya Medical Research Institute/USAMRU (Kisumu county) 4. KEMRI CMR-Kar Geno Research Centre (Kisumu county) 5. KEMRI CMR-Kar Geno Research Centre (Kisumu county) 6. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county) 7. KEMRI/ CDC (Kisumu county) 8. KEMRI (Kisumu county) 9. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county) 10. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county) |
View |
25. |
ECCT/23/01/07 | Moderna 1273 A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age |
Principal Investigator(s) 1. Dr. Lucas Otieno Tina Otieno Tina Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. KEMRI/USAMRD (Kericho county) 3. Kenya Medical Research Institute/USAMRU (Kisumu county) 4. KEMRI CMR-Kar Geno Research Centre (Kisumu county) 5. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county) 6. KEMRI/ CDC (Kisumu county) 7. KEMRI (Kisumu county) 8. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county) 9. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county) |
View |